Market capitalization | $5.18b |
Enterprise Value | $5.50b |
P/E (TTM) P/E ratio | 41.10 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.64 |
P/S ratio (TTM) P/S ratio | 4.37 |
P/B ratio (TTM) P/B ratio | 3.51 |
Dividend yield | 0.28% |
Last dividend (FY23) | $0.06 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
11 Analysts have issued a Stevanato Group Spa forecast:
11 Analysts have issued a Stevanato Group Spa forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,186 1,186 |
5%
5%
|
|
Gross Profit | 317 317 |
9%
9%
|
|
EBITDA | 249 249 |
10%
10%
|
EBIT (Operating Income) EBIT | 164 164 |
17%
17%
|
Net Profit | 124 124 |
21%
21%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates in Biopharmaceutical and Diagnostic Solutions and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.
Head office | Italy |
CEO | Franco Stevanato |
Founded | 1996 |
Website | www.stevanatogroup.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.